Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Reneo Pharmaceuticals logo

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

Advanced Chart

Key Stats

Today's Range
$1.68
$1.90
50-Day Range
$1.31
$1.82
52-Week Range
$0.98
$9.21
Volume
437,523 shs
Average Volume
250,384 shs
Market Capitalization
$60.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Stock News Headlines

Onkure Therapeutics Inc (OKUR)
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Missed Nvidia? This Under-the-Radar AI Stock Could Be Next Musk's AI empire is just beginning — and one overlooked company could be at the center of it all. We reveal everything in this exclusive Memorial Day webinar.
See More Headlines

RPHM Stock Analysis - Frequently Asked Questions

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) released its earnings results on Monday, March, 27th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.03.

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reneo Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Invesco QQQ (QQQ), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/27/2023
Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-77,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.66 per share
Price / Book
0.68

Miscellaneous

Free Float
27,439,000
Market Cap
$60.84 million
Optionable
Optionable
Beta
0.21
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:RPHM) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners